Editor in Chief
Michael J. Loeffelholz
Professor in the Department of Pathology, Director of the Clinical Microbiology Laboratory at the University of Texas Medical Branch (UTMB) at Galveston.

Editors
Richard L. Hodinka
Professor in the Microbiology Department and Chair of the Department of Biomedical Sciences at the University of South Carolina School of Medicine

Stephen A. Young
Director of Research and Clinical Trials at TriCore Reference Laboratories

Benjamin A. Pinsky
Assistant Professor in the Departments of Pathology and Medicine, Division of Infectious Diseases and Geographic Medicine, at the Stanford University School of Medicine
DEDICATION

We dedicate this edition of the Clinical Virology Manual to our families for their patience and support during this and our other professional endeavors. We are truly blessed to be part of their lives and to receive their unconditional love.

We would also like to thank, and gratefully acknowledge the support and leadership of, our close colleague, mentor, and friend, Dr. Steven Specter, who has worked tirelessly over the years in delivering the first four editions of the Manual, to advance the field of viral diagnostics, and to provide a forum for clinical virologists, academicians, and clinicians to present and discuss the latest scientific discoveries. We will be forever appreciative of his unwavering efforts.
# Contents

<table>
<thead>
<tr>
<th>Contributors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Editor Biographies</td>
</tr>
<tr>
<td>Preface to the Fifth Edition</td>
</tr>
</tbody>
</table>

## SECTION I

### GENERAL TOPICS IN CLINICAL VIROLOGY

1. **The Taxonomy, Classification, and Characterization of Medically Important Viruses** / 3  
   STEVEN J. DREWS

2. **Quality Assurance and Quality Control in Clinical and Molecular Virology** / 27  
   MATTHEW J. BANKOWSKI

3. **Regulatory Compliance** / 35  
   Linoj Samuel

4. **Laboratory Safety** / 41  
   K. Sue Kehl

5. **Laboratory Design** / 51  
   MATTHEW J. BINNICKER

## SECTION II

### LABORATORY PROCEDURES FOR DETECTING VIRUSES

6. **Specimen Requirements Selection, Collection, Transport, and Processing** / 59  
   Reeti Khare and Thomas E. Grys

7. **Primary Isolation of Viruses** / 79  
   Marie L. Landry and Diane Leland

8. **Viral Antigen Detection** / 95  
   Diane S. Leland and Ryan F. Relich

9. **Serologic (Antibody Detection) Methods** / 105  
   Dongxiang Xia, Debra A. Wadford, Christopher P. Preas, and David P. Schnurr

10. **Nucleic Acid Extraction in Diagnostic Virology** / 117  
    Raymond H. Widen and Suzane Silbert

11. **Nucleic Acid Amplification by Polymerase Chain Reaction** / 129  
    Ana María Cardenas and Kevin Alby

12. **Isothermal Nucleic Acid Amplification Methods** / 137  
    Harald H. Kessler and Evelyn Stelzl

13. **Quantitative Molecular Methods** / 145  
    Natalie N. Whitfield and Donna M. Wolk

14. **Signal Amplification Methods** / 167  
    Yun (Wayne) Wang

15. **DNA Sequencing for Clinical and Public Health Virology: Some Assembly Required** / 173  
    Joanne Bartkus

16. **Phenotypic and Genotypic Antiviral Susceptibility Testing** / 201  
    Martha T. Van Der BEEK and Eric C. J. Claas
<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>Point-of-Care Diagnostic Virology / 229</td>
<td>James J. Dunn and Lakshmi Chandramohan</td>
</tr>
<tr>
<td>18</td>
<td>Future Technology / 243</td>
<td>Erin McElvania Tekippe and Carey-Ann D. Burnham</td>
</tr>
<tr>
<td></td>
<td><strong>SECTION III</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>VIRAL PATHOGENS</strong></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Respiratory Viruses / 257</td>
<td>Christine Robinson, Michael J. Loeffelholz, and Benjamin P. Pinsky</td>
</tr>
<tr>
<td>20</td>
<td>Enteroviruses and Parechoviruses / 277</td>
<td>M. Steven Oberste and Mark A. Pallansch</td>
</tr>
<tr>
<td>21</td>
<td>Measles, Mumps, and Rubella Viruses / 293</td>
<td>William J. Bellini, Joseph P. Icenogle, and Carole J. Hickman</td>
</tr>
<tr>
<td>22</td>
<td>Gastrointestinal Viruses / 311</td>
<td>Michael D. Bowen</td>
</tr>
<tr>
<td>23</td>
<td>Hepatitis A and E Viruses / 329</td>
<td>Gilberto Vaughan and Michael A. Purdy</td>
</tr>
<tr>
<td>24</td>
<td>Hepatitis B and D Viruses / 341</td>
<td>Rebecca T. Horvat</td>
</tr>
<tr>
<td>25</td>
<td>Hepatitis C Virus / 351</td>
<td>Melanie Mallory and David Hillyard</td>
</tr>
<tr>
<td>26</td>
<td>Herpes Simplex Viruses and Varicella Zoster Virus / 363</td>
<td>Scott H. James and Mark N. Prichard</td>
</tr>
<tr>
<td>27</td>
<td>Cytomegalovirus / 373</td>
<td>Preeti Pancholi and Stanley I. Martin</td>
</tr>
<tr>
<td>28</td>
<td>Epstein-Barr Virus / 387</td>
<td>Derrick Chen and Belinda Yen-Lieberman</td>
</tr>
<tr>
<td>29</td>
<td>Human Herpesviruses 6, 7, and 8 / 399</td>
<td>Sheila C. Dollard and Timothy M. Karnauchow</td>
</tr>
<tr>
<td>30</td>
<td>Human Papillomaviruses / 413</td>
<td>Susan Novak-Weekley and Robert Pretorius</td>
</tr>
<tr>
<td>31</td>
<td>Human Polyomaviruses / 427</td>
<td>Rebecca J. Rockett, Michael D. Nissen, Theo P. Sloots, and Seweryn Bialasiewicz</td>
</tr>
<tr>
<td>32</td>
<td>Paroviruses / 443</td>
<td>Richard S. Buller</td>
</tr>
<tr>
<td>33</td>
<td>Poxviruses / 457</td>
<td>Ashley V. Kondas and Victoria A. Olson</td>
</tr>
<tr>
<td>34</td>
<td>Rabies Virus / 473</td>
<td>Robert J. Rudd and April D. Davis</td>
</tr>
<tr>
<td>35</td>
<td>Arboviruses / 493</td>
<td>Laura D. Kramer, Elizabeth B. Kauffman, Norma P. Tavakoli</td>
</tr>
<tr>
<td>36</td>
<td>Animal-Borne Viruses / 515</td>
<td>Gregory J. Berry, Michael J. Loeffelholz, and Gustavo Palacios</td>
</tr>
<tr>
<td>37</td>
<td>Human Immunodeficiency Viruses and Human T-lymphotropic Viruses / 527</td>
<td>Jörg Schüpbach</td>
</tr>
<tr>
<td>38</td>
<td>Chlamydiae / 545</td>
<td>Barbara Van der Pol and Charlotte A. Gaydos</td>
</tr>
<tr>
<td>39</td>
<td>The Human Virome / 561</td>
<td>Matthew C. Ross, Nadim J. Ajami, and Joseph F. Petrosino</td>
</tr>
<tr>
<td>40</td>
<td>Human Susceptibility and Response to Viral Diseases / 567</td>
<td>Ville Peltola and Jorma Ilonen</td>
</tr>
</tbody>
</table>

APPENDIXES: REFERENCE VIROLOGY LABORATORIES

APPENDIX 1  Reference Virology Laboratory Testing Performed at the Centers for Disease Control / 581
Roberta B. Carey

APPENDIX 2  Public Health Laboratory Virology Services / 585
Jane Getchell

APPENDIX 3  International Reference Laboratories Offering Virology Services / 595
Ariel I. Suarez and Cristina Videla

INDEX / 607
Contributors

NADIM AJAMI
Baylor College of Medicine, Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and Microbiome Research Houston, TX 77030

KEVIN ALBY
University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, PA 19104

MATTHEW J. BANKOWSKI
Diagnostic Laboratory Services (The Queen’s Medical Center) Aiea, HI 96701

JOHN A. BURNS
School of Medicine, Department of Pathology, University of Hawaii at Manoa Honolulu, HI 96813

JOANNE BARTKUS
Minnesota Department of Health, Public Health Laboratory St Paul, MN 55164

WILLIAM BELLINI
Centers for Disease Control and Prevention, MMRHLB(DVD)/NCIRD Atlanta, GA 30329

GREGORY BERRY
University of Texas Medical Branch, Clinical Microbiology Laboratory Galveston, TX 77555

SEWERYN BIALASIEWICZ
Centre for Children’s Health Research, Children’s Health Queensland, and the Child Health Research Centre, The University of Queensland South Brisbane, QLD 4101 Australia

MATTHEW J. BINNICKER
Mayo Clinic, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology Rochester, MN 55905

MICHAEL D. BOWEN
Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases Atlanta, GA 30333

RICHARD BULLER
Washington University School of Medicine, Department of Pediatrics Saint Louis, MO 63110

CAREY-ANN BURNHAM
Washington University School of Medicine, Department of Pathology & Immunology Saint Louis, MO 63110

ANA MARIA CARDENAS
University of Pennsylvania, Department of Pathology and Laboratory Medicine Philadelphia, PA 19103

ROBERTA CAREY
Centers for Disease Control and Prevention, Laboratory Quality Management Atlanta, GA 30333

LAKSHMI CHANDRAMOHAN
Texas Children’s Hospital, Department of Pathology Houston, TX 77030

DERRICK CHEN
Mayo Clinic, Laboratory Medicine and Pathology Rochester, MN 55905

ERIC C.J. CLAAS
Leiden University Medical Centre, Medical Microbiology Leiden 2333 ZA

APRIL DAVIS
New York State Health Department, Wadsworth Center Slingerlands, NY 12159

SHEILA C. DOLLARD
Centers for Disease Control and Prevention, Division of Viral Diseases Atlanta, GA 30329

STEVEN J. DREWS
ProvLab Alberta, Diagnostic Virology University of Alberta, Department of Laboratory Medicine and Pathology Edmonton, AB Canada
CONTRIBUTORS

JAMES DUNN
Texas Children’s Hospital, Department of Pathology Houston, TX 77030

CHARLOTTE GAYDOS
Johns Hopkins University School of Medicine, Division of Infectious Diseases Baltimore, MD 21205

JANE GETCHELL
Public Health Laboratory Consultant Bethany Beach, DE 19930

THOMAS GRYS
Mayo Clinic in Arizona, Department of Laboratory Medicine and Pathology Phoenix, AZ 85054

CAROLE HICKMAN
Centers for Disease Control and Prevention, MMRHLB/DVD/NCIRD Atlanta, GA 30329

REBECCA HORVAT
University of Kansas Medical Center, Department of Pathology Kansas City, Kansas 66160

JOSEPH ICENOGLE
Centers for Disease Control and Prevention, MMRHLB/DVD/NCIRD Atlanta, GA 30329

JORMA ILONEN
University of Turku, The Immunogenetics Laboratory Turku, Finland

SCOTT JAMES
University of Alabama at Birmingham, Department of Pediatrics Birmingham, AL 35233

TIMOTHY KARNAUCHOW
Children’s Hospital of Eastern Ontario, Division of Virology Ottawa, Ontario K1H 8L1 Canada

ELIZABETH KAUFFMAN
New York State Department of Health, Wadsworth Center Slingerlands, NY 12159

SUE KEHL
Medical College of Wisconsin, Department of Pathology Milwaukee, WI 53226

HARALD KESSLER
Medical University of Graz Graz, Austria

REETI KHARE
Northwell Health Laboratories, Department of Pathology and Laboratory Medicine Lake Success, NY 11042

ASHLEY KONDAS
Centers for Disease Control and Prevention, Poxvirus and Rabies Branch Atlanta, GA 30333

LAURA KRAMER
New York State Department of Health, Wadsworth Center, and Department of Biomedical Sciences, SUNY Albany Slingerlands, NY 12159

MARIE LOUISE LANDRY
Yale University, Departments of Laboratory Medicine and Internal Medicine (Infectious Diseases) New Haven, CT 06520

DIANE LELAND
Indiana University School of Medicine, Department of Pathology and Laboratory Medicine Indianapolis, IN 46202

MICHAEL LOEFFELHOLZ
University of Texas Medical Branch, Clinical Microbiology Laboratory Galveston, TX 77555

STANLEY MARTIN
The Ohio State University Wexner Medical Center, Division of Infectious Diseases; Transplant Infectious Diseases Service Columbus, OH 43210

MICHAEL NISSEN
Children’s Health Queensland, Queensland Children’s Medical Research Institute Brisbane, Queensland 4029 Australia

SUSAN NOVAK-WEEKLEY
Southern California Permanente Medical Group, Regional Reference Laboratories, Microbiology North Hollywood, CA 91605

M. STEVEN OBERSTE
Centers for Disease Control and Prevention, Poxvirus and Rabies Branch Atlanta, GA 30333

VICTORIA OLSON
Centers for Disease Control and Prevention, Poxvirus and Rabies Branch Atlanta, GA 30333

GUSTAVO PALACIOS
USAMRIID, Center for Genome Sciences Frederick, MD 21702

MARK PALLANSCH
Centers for Disease Control and Prevention, Division of Viral Diseases Atlanta, GA 30329

PREETI PANCHOLI
The Ohio State University Wexner Medical Center, Department of Pathology Columbus, OH 43205

VILLE PELTOLA
Turku University Hospital, Department of Pediatrics and Adolescent Medicine Turku 20521 Finland

JOSEPH PETROSINO
Baylor College of Medicine, Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and Microbiome Research Houston, TX 77030

CHRISTOPHER PREAS
California Department of Public Health, Viral and Rickettsial Disease Laboratory Richmond, CA 94804

ROBERT PRETORIUS
Southern California Permanente Medical Group—Fontana, Obstetrics and Gynecology Fontana, CA 92445

MARK PRICHARD
University of Alabama at Birmingham, Department of Pediatrics Birmingham, AL 35233

MICHAEL PURDY
Centers for Disease Control and Prevention, Division of Viral Hepatitis Atlanta, GA 30329
RYAN RELICH  
Indiana University School of Medicine, Department of Pathology and Laboratory Medicine Indianapolis, IN 46202

REBECCA ROCKETT  
Centre for Infectious Diseases & Microbiology - Public Health (CIDM-PH) Institute of Clinical Pathology & Medical Research (ICPMR) Westmead Hospital, Westmead NSW, 2145, Sydney, Australia

MATTHEW ROSS  
Baylor College of Medicine, Department of Molecular Virology and Microbiology, Alkek Center for Metagenomics and Microbiome Research Houston, TX 77030

ROBERT RUDD  
New York State Health Department, Wadsworth Center Slingerlands, NY 12159

LINOJ SAMUEL  
Henry Ford Health System, Department of Pathology Detroit, MI 48202

DAVID SCHNURR  
California Department of Public Health, Viral and Rickettsial Disease Laboratory Richmond, CA 94804

JÖRG SCHÜPBACH  
University of Zurich, Institute of Medical Virology, Swiss National Center for Retroviruses Zurich CH-8057 Switzerland

SUZANE SILBERT  
Tampa General Hospital, Department of Pathology, Esoteric Testing/R&D Tampa, FL 33606

THEO SLOOTS  
Centre for Children’s Health Research, Children’s Health Queensland, and the Child Health Research Centre, The University of Queensland South Brisbane, QLD 4101 Australia

EVELYN STELZL  
Medical University of Graz Graz, Austria

ARIEL SUAREZ  
IACA Laboratorios, Molecular Biología Bahia Blanca, Buenos Aires B8000FIB Argentina

NORMA TAVAKOLI  
New York State Department of Health, Wadsworth Center, And Department of Biomedical Sciences, State University of New York Albany, NY 12208

ERIN MCELVANIA TEKIPPE  
University of Texas Southwestern Medical Center, Department of Pathology and Pediatrics Dallas, TX

MARTHA T. VAN DER BEEK  
Leiden University Medical Centre, Medical Microbiology Leiden 2333 ZA Netherlands

BARBARA VAN DER POL  
University of Alabama at Birmingham School of Medicine, Division of Infectious Diseases Birmingham, AL 35294

GILBERTO VAUGHAN  
Centers for Disease Control and Prevention, Division of Viral Hepatitis Atlanta, GA 30329

CRISTINA VIDELA  
CEMIC Virology Buenos Aires C1431FWO Argentina

DEBRA WADFORD  
California Department of Public Health, Viral and Rickettsial Disease Laboratory Richmond, CA 94804

YUN F. WANG  
Emory University School of Medicine, Department of Pathology & Laboratory Medicine Atlanta, GA 30303

NATALIE WHITFIELD  
OpGen Clinical Services Laboratory Gaithersburg, MD 20878

RAYMOND WIDEN  
Tampa General Hospital, Pathology Department, Esoteric Testing/R&D Tampa, FL 33606

DONNA WOLK  
Geisinger Health Systems, Dept. of Laboratory Medicine Danville, PA 17822

DONGXIANG XIA  
California Department of Public Health, Viral and Rickettsial Disease Laboratory Richmond, CA 94804

BELINDA YEN-LIEBERMAN  
Cleveland Clinic, Laboratory Medicine Cleveland, OH 44195
Editor Biographies

Michael J. Loeffelholz is a Professor in the Department of Pathology, Director of the Clinical Microbiology Laboratory at the University of Texas Medical Branch (UTMB) at Galveston, and Director of the American Society for Microbiology (ASM) CPEP-accredited Medical Microbiology Fellowship program at UTMB. Dr. Loeffelholz is also an editor of the *Journal of Clinical Microbiology*. He has served on a number of committees, including the Pan American Society for Clinical Virology (PASCV), ASM Committee on Professional Affairs, CDC Board of Scientific Counselors/Office of Infectious Diseases, and the Association of Public Health Laboratories Board of Directors. Dr. Loeffelholz is a diplomate of the American Board of Medical Microbiology (ABMM).

Richard L. Hodinka is a Professor in the Microbiology Department and Chair of the Department of Biomedical Sciences at the University of South Carolina School of Medicine, Greenville. Dr. Hodinka’s clinical and research interests involve pediatric viral diseases, detection and monitoring of viral infections in pediatric and adult immunocompromised hosts, and the development and study of rapid and accurate methods for the diagnosis of infectious diseases; current emphasis is on molecular technologies and automated instrumentation for the greatest impact on the care and management of ill patients. Dr. Hodinka has served as President and a Council Member for the PASCV, as a member of the International Scientific Advisory Committee for the Asia Pacific Congress of Medical Virology, and on a number of ASM committees. Dr. Hodinka has published extensively and is the author of a number of original scientific publications, review articles, and book chapters.

Stephen A. Young is Director of Research and Clinical Trials at TriCore Reference Laboratories and Professor (emeritus) in the Department of Pathology at the University of New Mexico. Dr. Young served as a collaborator in the Multi-Center AIDS Cohort Study for 25 years and is a co-investigator on two NIH grants affiliated with the cohort. He is involved in an active research program to evaluate and develop diagnostic products for clinical microbiology and has completed approximately 100 FDA *in vitro* diagnostic device trials or market evaluations of diagnostic tests. Dr. Young is a diplomate of the ABMM.

Benjamin A. Pinsky is an Assistant Professor in the Departments of Pathology and Medicine, Division of Infectious Diseases and Geographic Medicine, at the Stanford University School of Medicine and is the Medical Director of the Clinical Virology Laboratory for Stanford Health Care and Stanford Children’s Health. Dr. Pinsky is on the editorial boards of several journals including the *Journal of Clinical Microbiology* and *Clinical Microbiology Reviews*. He has also served on a number of committees, including the PASCV, College of American Pathologists Microbiology Resource Committee, and the Association for Molecular Pathology Clinical Practice Committee. Dr. Pinsky is board certified in Clinical Pathology by the American Board of Pathology.
Preface to the Fifth Edition

The aims of the fifth edition of the Clinical Virology Manual remain the same as prior editions and include serving as a reference source to healthcare professionals and laboratorians in providing clinical and technical information regarding viral diseases and the diagnosis of viral infections.

This new edition includes 40 chapters and 3 appendices and, similar to the organization of prior additions, consists of the four sections: general topics, laboratory procedures, viral pathogens, and the appendices. We have modified the content of the appendices to provide basic but practical information on reference virology laboratories at both the national and international levels. The viral pathogen chapters have a consistent organization, with proportionally more content dedicated to diagnostics and testing. Additionally, a new section, with the heading of “Diagnostic Best Practices”, has been included in each viral pathogen chapter. The section summarizes recommendations for diagnostic testing and cites evidence-based guidelines when available.

The past several years have been very challenging, as well as exciting, for diagnostic virologists, with outbreaks of enterovirus D68, measles virus, mumps virus, norovirus, Ebola virus, and, most recently, Zika virus. In addition, there is continued emergence of chikungunya, dengue, and influenza viruses, highlighted by the influenza pandemic of 2009. The landscape of hepatitis C virus has changed, and will continue to change dramatically, with the availability of new classes of direct-acting antiviral drugs that provide an excellent probability of cure.

This edition has incorporated these significant events to the extent allowed by the production schedule. We thank the authors for their contributions, particularly during this very busy time for virologists. We also thank the staff of the American Society for Microbiology Press for their support and hard work in bringing this edition to fruition.

The fifth edition of the Manual also brings a major change in editors, as a new editor has been added and a previous editor has cycled off. Also, after successfully leading this series through four editions, Dr. Steven Specter has passed on the reins of Editor-in-Chief. We hope that this edition is a credit to Dr. Specter, as well as to other prior editors, Drs. Lancz and Wiedbrauk.

MICHAEL J. LOEFFELHOLZ
RICHARD L. HODINKA
STEPHEN A. YOUNG
BENJAMIN A. PINSKY
Subject Index

A
ABI SOLiD, 179
Abnova, 123
Acquired immunodeficiency syndrome (AIDS)
cytomegalovirus infection with, 381
HHV-6 in patients with, 69
ACS, See American Cancer Society
Acute bronchitis, 9
Acute epidemic hemorrhagic conjunctivitis,
Acute hemorrhagic conjunctivitis,
Acute myocardiitis, enteroviruses with, 283
Acute nasopharyngitis, 9, 12, 13
Acute meningitis, 283
Acute myocarditis, enteroviruses with, 283
Acute myeloblastosis virus, 6
Acute respiratory infections, 12
Adeno-associated dependovarivirus virus, 7
Adenovirus. See also Enteric adenoviruses;
Mastadenovirus
best practices for, 272
biology of, 259
cell cultures of, 87
classification of, 259
clinical significance of, 264–265
diagnosis of, 269–270
epidemiology of, 262
human, 17
prevention of, 267
relative importance of, 259, 262
specimen information for exanthems with, 61
specimen information for gastroenteritis with, 65
specimen information for ocular infections with, 70
specimen information for respiratory disease with, 60
taxonomy determination for, 21–22
treatment of, 267
Adult T-cell leukemia/lymphoma (ATLL), 531
treatment of, 532
Aichi virus, 320–321
Aichivirus A, 9
AIDS. See Acquired immunodeficiency syndrome
Akhtema virus, 459
Alere I Influenza, 138, 140
Alere I Influenza A&B assay, 247
Alere Q NAT system, 248
Alphacoronavirus, 8
Alphapapillomavirus, 6
Alphatorquevirus, 7
Alphavirus, 493–495
clinical significance of, 500
epidemiology of, 497–498
taxonomy and characterization of, 10
treatment for, 417
HHV-6 in patients with, 69
cytomegalovirus infection with, 381
hemagglutination inhibition in, 107–108
hepatitis E virus with, 105
immunofluorescence assays in, 108–109
immunoglobulin M determinations in, 111–113
neutralization in, 106–107
western blot in, 113–114
Antigen detection assays, 237
arboviruses diagnosis with, 505
gastrointestinal viruses in, 231–232
hepatitis B virus detection with, 347
HIV-6 diagnosis with, 404, 407
HPV identification with, 421
influenza virus in, 230
norovirus in, 231–232
respiratory syncytial virus in, 229–231
respiratory viruses in, 229–231
rotavirus in, 231
Antigene assay, cytomegalovirus
biology of, 208, 349
antigen detection for diagnosis of, 505
viral classification of, 515
diagnostic best practices for, 521
detection and diagnosis of, 505–521
diagnostics best practices for, 521–522
epidemiology of, 516–517
prevention of, 519–520
treatment for, 519–520
viral classification of, 515–516
Anogenital warts, 416
culture-based systems in, 201
hepatitis B virus, 208, 349
hepatitis C virus, 208, 212, 220–221
herpes simplex virus, 203–204, 209–219
HIV, 221–222
influenza viruses, 204, 206, 208
PCR-based methods in, 202
phenotypic and genotypic, 201–222
sequencing methods in, 202–203
vaccines, rotavirus, 202–203
poxvirus, 220, 221
Aptima HIV-1 Quant Dx, 138, 139
Aptima HPV, 138, 139
Arboviruses
Alphavirus, 493–495, 497–498, 500, 502
antigen detection for diagnosis of, 505
best practices for, 507–508
biology of, 493–495
blood-donor screening for, 507

Downloaded from www.asmscience.org by
On: Sun, 19 May 2019 01:42:16
IP: 54.70.40.11
Arboviruses (continued)
Bunyaviridae, 495, 497, 499–503
clinical significance of, 502–502
complement fixation in diagnosis of, 506
detection and diagnosis of
epidemiologic surveillance and research, 505–507
routine diagnostics, 503–505
epidemiology of, 495–500
Flaviviridae, 495, 496, 498–503
geographic distribution of, 504
hemagglutination inhibition in diagnosis of, 505–506
IgM and IgG antibody detection for
microarray technology in diagnosis of, 507
microsphere immunoassays in diagnosis of, 506
NGS in diagnosis of, 507
plaque-reduction neutralization in diagnosis of, 506
prevention of, 502–503
public health laboratory testing for, 585–589
real-time RT-PCR in diagnosis of, 506–507
RT-PCR in diagnosis of, 506
Togaviridae, 493–495, 500
treatment for, 502–503
vaccination for, 502–503
vector control for, 502
viral classification of, 493–495
ebivirus infection for, 505
 Arenaviruses
biology of, 515
clinical significance of, 517–518
detection and diagnosis of, 520
diagnostic best practices for, 521–522
epidemiology of, 516
prevention of, 519
taxonomy and characterization of, 11
treatment for, 519
viral classification of, 515
Aries, 125
Arenaviridae, database website for, 18
Arthropod-borne viral fevers, 7
ASCCP. See American Society of
Colposcopy and Cervical Pathology
ASCP. See American Society of Clinical
Pathology
ASRs. See Analyte specific reagents
Astroviruses
biology of, 313–314
clinical significance of, 316
database website for, 17
detection and diagnosis of
cell culture, 319
electron microscopy, 313, 319
immunoassays, 319
qRT-PCR assays, 319
RT-PCR assays, 319
serology, 318–319
epidemiology of, 315
specimen information for gastroenteritis with, 65
viral classification of, 313–314
ATL. See Adult T-cell leukemia/lymphoma
Atypical and low-grade squamous cell
lesion of cervix, 415
Ausdyk virus, 459
Australian bat lyssavirus, 13
Australian encephalitis, 9
Autoimmune diseases, EBV associated with, 391
Avian myeloblastosis virus (AMV), 130
B
Bacteriophages, 563
Baltimore classification
double-stranded DNA viruses, 5–6
double-stranded RNA viruses, 7
negative sense single-stranded RNA viruses, 11–13
positive sense single-stranded RNA viruses, 8–10, 14
single-stranded DNA viruses, 7
six groups of, 14
Banna virus, 7
Bar coding, 174
Barnah Forest virus (BFV), 10, 494
Bat-associated viruses, database website for, 17
Bayou virus, 11
BCA assay. See Biobarcode amplification assay
BD MAX, 124
BD ProbeTec herpes simplex viruses, 138, 139
BD Veritor System Flu A+B Immunoassay, 246–247
Bacteriavirus, 8
Betapapillomavirus
Betacoronavirus
Baltimore classification
double-stranded DNA viruses, 5–6
double-stranded RNA viruses, 7
negative sense single-stranded RNA viruses, 11–13
positive sense single-stranded RNA viruses, 8–10, 14
single-stranded DNA viruses, 7
six groups of, 14
Banna virus, 7
Bag coding, 174
Barnah Forest virus (BFV), 10, 494
Bat-associated viruses, database website for, 17
Bayou virus, 11
BCA assay. See Biobarcode amplification assay
BD MAX, 124
BD ProbeTec herpes simplex viruses, 138, 139
BD Veritor System Flu A+B Immunoassay, 246–247
Bacteriavirus, 8
Betapapillomavirus
Betacoronavirus
Baltimore classification
double-stranded DNA viruses, 5–6
double-stranded RNA viruses, 7
negative sense single-stranded RNA viruses, 11–13
positive sense single-stranded RNA viruses, 8–10, 14
single-stranded DNA viruses, 7
six groups of, 14
Banna virus, 7

BKV virus (BKV)
Quantitative detection of, 159
specimen collection for, 66
specimen information for ocular infections with, 70
Black Creek Canal Virus, 11
Bleach, laboratory safety with, 44
Bloodborne Pathogen Standard, 44, 47
Blood transfusion, human herpes virus 8 with, 401
BMBL5. See Biosafety in Microbiological and
Biomedical Laboratories fifth edition
Bocaparvovirus, 7
Bolivian hemorrhagic fever, 19
Borna disease virus, 12
Borna virus, 12
Bourbon virus, specimen information for
neurological infections with, 62
Bovine leukemia virus (BLV), 459
Branched DNA technology (bDNA)
application in virology laboratory of, 170
characteristics of, 168–170
comparison of HC2 with, 170
principles of, 168–170
scheme for, 169
Breast cancer, EBV associated with, 390–391, 396
Bronchitis, 12–13
BSC. See Biosafety cabinet
BSL. See Biosafety containment levels
Butaviruses, 320
Buffalo green monkey kidney (BGMK) cells, 83
Bandhuyaru ebolavirus, 12
Bunyaviridae, 495
clinical significance of, 501–502
epidemiology of, 499–500
family summarized, 497
vaccination for, 503
Bunyaviruses, caution in handling
specimens from, 73
Buamba virus, 11

C
Cache Valley Virus, 83
Caliciviruses
biology of, 311
clinical significance of, 315
detection and diagnosis of
electron microscopy, 313, 317
immunoassays, 317
qRT-PCR assays, 317
RT-PCR assays, 317
serology, 317
epidemiology of, 314
viral classification of, 311
California (La Crosse) encephalitis
specimen information for neurological infections with, 62
taxonomy and characterization of, 11
Camelpox virus, 459
CAP, 36–37
CAPA. See Corrective and preventive action
Cardio-pulmonary syndrome, 11
Cardiovirus
Casjens and Kings classification, 14
Corrective and preventive

Assessment
Cajgos. See Committee on Conformity Assessment
Cajgos. See Committee on Conformity Assessment
CCHFV. See Crimean-Congo hemorrhagic fever virus
CDC. See Centers for Disease Control and Prevention

Cell cultures
of adenoviruses, 87
astroviruses diagnosis with, 319
of CMV, 83, 87
cultivated, 84–85
conventional, 80
cytomegalovirus diagnosis with, 376, 378
cytotoxic effect in, 80–81
detection methods for, 81
diagnostic applications of, 89–90
tropic adenoviruses diagnosis with, 319
evertheless, 87
equipment needed for, 79–80
genetically modified, 85–86
hemadsorption, 81
herpes simplex virus diagnosis with,
367–368
of HSV, 81, 86
H&V mix, 85
incubation period for, 80–81
of influenza virus, 81, 88
inoculation of, 80–81
mixed, 84–85
monoclonal antibody pools with,
84–85
obtaining specimens for, 80
of parainfluenza virus, 81–82, 88
processing specimens for, 80
quality assurance for, 31, 88–89
of rhinoviruses, 88
R-mix, 84–85
R-mix Too, 84–85
rotavirus diagnosis with, 317
of RSV, 88
sensitivity in, 79
shell vial (centrifugation) technique in,
83–84
Super E-mix, 85–86
supplies needed for, 79–80
troubleshooting for, 88–89
types of, 79, 80
uninfected, 82
varicella-zoster virus diagnosis with, 368,
369
viral diagnosis with, 79
viruses commonly isolated in, 86–88
virus-induced effect detection in, 83–84
virus isolation in, 79–83
of VZV, 81, 87

Centers for Disease Control and Prevention (CDC), 35
biosafety introduced by, 41
bloodborne pathogens precautions with,
44
disinfection guidelines from, 42
gastroenteritis recommendations, 65
laboratory design guidance by, 54
risk assessment, 42
virology tests by, 581–584

Centers for Medicare and Medicaid Services (CMS), 27, 35
certificate of compliance from, 36
Central Asian hemorrhagic fever, 19
Centrifugation, in shell vial technique,
83–86
Centrifugation technique. See Shell vial technique

Cepheid GeneXpert, 133
Cepheid GeneXpert Omni, 247
Cervical cancer, 416–417
prevention of, 417
screening, 413
treatment of, 417
Cervical high-grade squamous cell lesion, 415
Cervical squamous cell carcinoma and adenocarcinoma, 415
Cecary disease, 14
Chandipura virus, 13
Changnúna virus, 7
Chemical Hygiene Plan (CHP), 43
Chickenpox. See Varicella
Chikungunya virus (CHIKV), 19, 494
clinical significance of, 500
epidemiology of, 498
public health laboratory testing for, 592
specimen information for infections with
joint pain with, 64
specimen information for neurological
infections with, 62
taxonomy and characterization of, 10
Chlamydiae
best practices for, 533–555
biology of, 545–546
classification of, 545
clinical significance of, 547
detection and diagnosis of, 548–553
epidemiology of, 546–547
prevention of, 547–548
sample collection for, 548–549
treatment for, 547–548
Chlamydia pneumoniae
best practices for, 555
clinical significance of, 547
detection and diagnosis of, 552–553
epidemiology of, 546–547
NAAT in diagnosis of, 553
prevention of, 548
serology in diagnosis of, 553
tissue culture in diagnosis of, 553
treatment for, 548
Chlamydia trachomatis
best practices for, 553–555
clinical significance of, 547
detection and diagnosis of, 549–552
direct immunoﬂuorescence for,
551–552
epidemiology of, 546
nucleic acid ampliﬁcation testing for,
550–551
point-of-care test for, 552
prevention of, 547–548
tissue culture for, 552
treatment for, 547
CHP. See Chemical Hygiene Plan

Chronic active EBV infection, 388, 392,
394–395
ChunLab, 179

CLIA. See Clinical Laboratory Improvement Amendments

CLIA Act of 1967 (CLIA 67), 35
CLIA Act of 1986 (CLIA 86), 35
CLIA Act of 1988 (CLIA 88), 35
clinical laboratory improvement
compliance requirements for, 36–37
test complexity with, 35–36
Clinical and Laboratory Standards Institute (CLSI), 35
guideline documents from, 28
laboratory personnel for, 27–28
procedure manual of, 28–30
Clinical Laboratory Improvement Amendments (CLIA)
accrediting agencies under, 36
proficiency testing, 32–33
regulatory compliance with, 36–37

CLSI. See Clinical and Laboratory Standards Institute

CMS. See Centers for Medicare and Medicaid Services

CMV. See Cytomegalovirus

COLA, 37
Colorado tick fever virus, 7
Cowpox virus (CPXV), 457, 459
historic standards for diagnosis of, 458
taxonomy and characterization of, 5
Coxackieviruses, history of discovery for, 277
efee. See Cytopathic effects

CPXV. See Cowpox virus

Crimean-Congo hemorrhagic fever virus
(CCHFV), 19, 497
BSL requirements under, 46
clinical significance of, 501
epidemiology of, 499
taxonomy and characterization of, 11

type lectins, 568, 569
Cutaneous HPV, 415–416

Cytomegalovirus (CMV)
AIDS with infection from, 381
antigenemia assay for, 377, 378
antiviral susceptibility testing for
clinical indications for, 203
assays for, 204–208
cellular resistance, 203–204
treatment for, 203–204
assays for, 204–208
best practices for, 380–382
biology of, 373
clinical significance of, 374
congenital, 380–381
detection and diagnosis of, 375–380
cell culture in, 81, 83, 87
future of, 382
diagnosis of antiviral resistance for, 380
epidemiology of, 373–374
histopathology for, 376, 378
infectious mononucleosis with, 380
measuring host immune reactivity to,
379–380
mutations in UL97-gene of, 207–208
mutations in UL97-gene of, 205–206
nucleic acid ampliﬁcation test for, 377
nucleic acid-based molecular methods for,
377
nucleic acid test for, 378–379
perinatal, 380–381
Cytomegalovirus (CMV) (continued)
- prevention of, 374–375
- quantitative detection of, 145–146,
  157–158
- repeat specimen collection for, 72
- serologic tests for, 375, 376, 378
- shell vial assay for, 376, 378
- specimen information for congenital
  infections with, 67
- specimen information for infectious
  mononucleosis with, 69
- specimen information for neurological
  infections with, 63
- specimen information for ocular
  infections with, 70
- specimen information for respiratory
  disease with, 60
- taxonomy and characterization of, 5
- transplant recipients with infection
  from, 381–382
- treatment for, 374–375
- tube culture for, 376
- viral classification of, 373
- virus culture for, 376, 378
Cytopathic effects (CPE), 42
- cell cultures with, 80–81
- poliovirus with, 277

D
- Deep sequencing, 174
- Deer Tick virus, 496
- Deltaarbovirus, 14
- Delavirus, 13
- Dengue fever, 9
- Dengue hemorrhagic fever, 9, 19
- Dengue virus, 496
  - antibody detection for, 105
  - clinical significance of, 500–501
- database website for, 17–19
- epidemiology of, 498
- public health laboratory testing for, 592
- specimen collection for, 66
- specimen information for hemorrhagic
  fevers with, 70
- specimen information for infections with
  joint pain with, 64
- specimen information for neurological
  infections with, 62
- taxonomy and characterization of, 9
- De novo assembly, 174
- Department of Health and Human
  Services (HHS), 35
- Department of Transportation (DOT), safe
  transport of specimens in, 48
- Dependoparvovirus, 443
- clinical significance of, 447
- epidemiology of, 445
- taxonomy and characterization of, 7
- Depth of coverage, 174
- DFA. See Direct immunofluorescence
- Diagnostic Hybrids (DHI), 96
- Diarrhea, enteroviruses with, 284
- DiaSorin, 138, 140
- Digital PCR (dPCR), 134, 135, 145, 149
  - as future technology, 244–245
- DIHS. See Drug-induced hypersensitivity
  syndrome
- Dimethyl sulfoxide (DMSO), 44
- Direct antigen detection, quality assurance
  with, 31–32
- Direct immunofluorescence (DFA), 95, 96
  - characteristics of, 101
- Clamydia trachomatis diagnosis with,
  551–552
- for rabies virus diagnosis with, 481–483
- Disinfection
- CDC guidelines for, 42
- chemical methods of, 42–43
- EPA approval of, 42
- laboratory safety with, 42–43
- UV light, 42
- DMSO. See Dimethyl sulfoxide DNA
  library, 174
- DNA sequencing, 173–193
- antiviral resistance detection with,
  189–191
- application of, 188–189
- bioinformatics for, 181–188
- FDA clearing of, 173
- HEV, 192
- MERS, 192
- next generation, 173–181
- pyrosequencing for, 175
- Sanger sequencing for, 173–175
- SARS, 192
- viral population analysis with, 189–192
- viromics with, 189
- virus detection and identification with,
  188–189
- virus genotyping with, 191–192
- DNA virus infections
  - antiviral therapy for, 203
  - diagnosis flow chart for, 203
  - treatment flow chart for, 203
- Documentation, 28
- DOT. See Department of Transportation
  (DOT).
- FilmArray BioThreat panel for, 249, 250
- Drug-induced hypersensitivity syndrome
  (DIHS), HEV-6 associated with,
  401
- Dugbe virus, 11
- Dye terminator, 179

E
- Eastern equine encephalitis virus (EEEV),
  10, 16, 494
- clinical significance of, 500
- epidemiology of, 497
- specimen information for neurological
  infections with, 62
- EasyMag, 123
- Ebola virus, 12, 19
  - BSL requirements under, 46
  - FilmArray BioThreat panel for, 249, 250
  - future technology for, 249–250
  - genotyping for, 192
  - ReEBOV Antigen Rapid Test for, 249,
    250
  - specimen information for hemorrhagic
    fevers with, 70
  - taxonomy and characterization of, 12
- Ebola Virus Rapid Antigen Diagnostic
  Test, 249, 250
- EBV. See Epstein-Barr virus
- EbolaVirus Rapid Antigen Diagnostic
  Test, 249, 250
- Ectromelia virus, 459
- EEV. See Eastern equine encephalitis virus
- EIA. See Enzyme immunoassay
- Electron microscopy
  - astroviruses diagnosis with, 313, 319
  - caliciviruses diagnosis with, 313, 317
  - enteric adenoviruses diagnosis with, 313,
    319
  - rotaviruses diagnosis with, 313, 318
- Electropherotyping
  - enteric adenoviruses diagnosis with, 319
  - rotaviruses diagnosis with, 318
- Electrospay ionization (ESI), 134–135
- PCR-ESI/MALDI, 134–135
- PCR-ESI-MS, 245
- ELISA. See Enzyme-linked immunosorbent
  assays
- ELVIS (Enzyme-linked inducible system), 86
- Emulsion PCR, 174
- Encephalitis, 14. See also California
  encephalitis; Eastern equine
  encephalitis virus; St. Louis
  encephalitis virus; Venezuelan
  encephalitis virus; Western
  equine encephalitis virus
- Australian, 9
- enteroviruses with, 283
- Japanese, 9, 496, 499, 501
- Murray Valley, 9, 496, 499
- tick-borne, 9, 496
- Venezuelan, 62
- Encephalomyelitis, 14
- Enigma MiniLab influenza A/B & RSV, 248
- Enteric adenoviruses
  - biology of, 314
  - clinical significance of, 316
  - detection and diagnosis of
    cell culture, 319
  - electron microscopy, 313, 319
  - electropherotyping, 319
  - immunoassays, 319–320
  - PCR assays, 320
  - real time PCR assays, 320
  - serology, 319
- Epidemiology of, 315
- viral classification of, 314
- Enteroviral encephalomyelitis, 8
- Enteroviral meningitis, 8
- Enteroviral vesicular pharyngitis, 8
- Enteroviruses, 277–287
  - acute hemorrhagic conjunctivitis with,
    283
  - acute myocarditis caused by, 283
  - age in risk for, 280–281
  - antigenicity of, 279
  - antivirals in treatment of, 284
  - asymptomatic infections with, 281–284
  - biology of, 277–279
  - classification of, 277–279
  - clinical syndromes with, 281–284
  - diagnosis of, 277–279
  - diagnostic best practices for, 287
  - diarrhoea with, 284
  - encephalitis with, 283
  - epidemiology of, 279–281
  - fever with maculopapular rash with, 283
  - geography factors with, 280–281
  - hand-foot-and-mouth disease with, 283
  - herpangina with, 283
  - history of discovery for, 277–278
  - incubation times for, 281
  - laboratory diagnosis of, 284–287
  - mode of transmission for, 279–280
  - molecular detection and characterization
    for, 285–286
  - molecular variation with, 281
  - neonatal enterovirus diseases with, 284
  - neutralization of, 279
  - nucleic acid detection assays for, 235
panniculitis myelitis caused by, 282
pathogenesis with, 281–284
pericarditis caused by, 283
pleuropneumonia with, 283
poliomyelitis with, 282
replication in cell culture of, 279
respiratory disease with, 284
risk groups for, 280–281
seasonal factors with, 280–281
sex in risk for, 280–281
socioeconomic factors with, 280–281
specimen information for congenital infections with, 68
specimen information for exanthems with, 61
specimen information for neurological infections with, 62
specimen information for ocular infections with, 70
specimen information for respiratory disease with, 60
structure of, 278–279
taxonomy and characterization of, 8
treatment and prevention of, 284
viral meningitis with, 282–283
virus isolation and identification for, 285

Enzyme immunoassay (EIA), 32, 98–100
application of, 110–111
characteristics of, 101
competitive, 110
immunohistochemical staining, 98–100
indirect, 109, 110
membrane, 98, 99, 101
method for, 109–110
microwell-based, 99–100, 101
multiplexing, 110
quality assurance for, 102, 111
troubleshooting for, 111

Enzyme-linked immunosorbent assays
(ELISA)
HHV-8 diagnosis with, 406
HTLV testing with, 539

Enzyme-linked inductive system. See ELVIS

EPA. See U.S. Environmental Protection Agency

EPC. See External positive controls

Epidermodysplasia verruciformis, 415

Erythroparvovirus
See also Parvovirus B19

Erythropoietin, 111

Erythroplakia, 19

Erythroplasias, 415

Erythropoietin receptor

Epstein-Barr virus (EBV)
breast cancer associated with, 390, 392–396
defense and prevention of, 519
diagnostic best practices for, 522
epidermodysplasia verruciformis associated with, 391, 392–396
EpMotion, 124

Epistaxis

Epstein-Barr virus (EBV)
breast cancer associated with, 390, 392–396
defense and prevention of, 519
diagnostic best practices for, 522
epidermodysplasia verruciformis associated with, 391, 392–396
EpMotion, 124

Epstein-Barr virus (EBV)
EpMotion, 124

Epstein-Barr virus (EBV)
Gastrointestinal viruses

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

Epstein-Barr virus (EBV)

H 
HAd. See Hemadsorption Hairy-cell leukemia, 14 HAM/TSP. See HTLV-1-associated myelopathy/tropical spastic paraparesis Hand-foot-and-mouth disease, enteroviruses with, 283 Hantavirus 
Hantaan virus, 11 Hanta(cardio)-pulmonary syndrome, 11 Hantavirus 
clinical Indications for, 203
definitions, antiviral resistance, 203–204
variables of, 203–204
antiviral therapies for, 366
antiviral treatment for, 203–204
assays for, 204, 209–219
best practices for, 369–370
biological characteristics of, 363
clinical significance of, 364–365
detection and diagnosis of
algorithm for, 368
analytical, 367–368
antibody, 368
cell culture in, 81, 87
nucleic acid amplification tests, 368–369
postanalytical, 369
preanalytical, 367
diagnostic approach to, 60, 65
epidemiology of, 364
mechanism of action of therapies for,
366–367
mutations in UL23-gene of, 209–212
mutations in UL30-gene of, 213–219
prevention of, 366–367
specimen information for congenital
infections with, 67
specimen information for exanthems with,
61
specimen information for genital
infections with, 66
specimen information for neurological
infections with, 62
specimen information for ocular
infections with, 70
specimen information for respiratory
disease with, 60
viral classification of, 363
*Herpesviridae*, database website for, 18
Herpesviruses. See also Human herpesvirus
historic standards for diagnosis of, 458
Herpes zoster. See Zoster
HEV. See Hepatitis E virus
HHS. See Department of Health and
Human Services
HHV-6. See Human herpes virus 6
HHV-6A. See Human herpes virus 6A
HHV-6B. See Human herpes virus 6B
HHV-7. See Human herpes virus 7
HHV-8. See Human herpes virus 8
HI. See Hemagglutination inhibition
Histopathology
cytomegalovirus diagnosis with, 376, 378
for parapoxviruses lesion, 463
for poxviruses lesion, 461
for yatapoxviruses lesion, 464
HIV. See Human immunodeficiency virus
HMV. See Human metapneumovirus
Holmes classification, 14
Hologic, 138
Horsepox virus, 459
HPV. See Human papillomavirus
HSV. See Herpes simplex virus
HTLV. See Human T-lymphotropic viruses
HTLV-1-associated myelopathy/tropical
spastic paraparesis (HAM/TSP), 531
treatment of, 532
Human adenovirus, database website for, 17
Human bacoviruses (HBoV1-4), 443
clinical significance of, 446–447
diagnosis of, HBoV1, 447–448, 450
epidemiology of, 444–445
Human coronaviruses (HCoV)
best practices for, 271
biology of, 258–259
classification of, 258–259
clinical significance of, 264
diagnosis of, 269
epidemiology of, 261–262
prevention of, 266–267
relative importance of, 258–259,
261–262
taxonomy and characterization of, 8
treatment of, 266–267
Human herpesvirus
specimen information for exanthems with,
61
specimen information for ocular
infections with, 70
Human herpesvirus 1, 5
Human herpesvirus 2, 5
Human herpesvirus 3, 5
Human herpes virus 4, 5
Human herpes virus 5, 5
Human herpes virus 6 (HHV-6)
AIDS in patients with, 69
antigen detection for diagnosis of, 404,
407
biology of, 399
clinical aspects of, 401–402
diagnostic best practices for, 407–408
DHIS associated with, 401
discovery of, 399
DNA for diagnosis of
in CSF, 405
in plasma, 404–405
in saliva, 405
epidemiology of, 400
immunocompetent hosts with infections
from, 401
immunocompromised hosts with
infections from, 401–402
laboratory diagnosis for, 404–405, 407
multiple sclerosis associated with, 401
nucleic acid detection for diagnosis of,
404, 407
prevention of, 403
qualitative PCR for diagnosis of, 404,
407
qualitative RTPCR for diagnosis of, 404,
407
serology for diagnosis of, 404
specimen selection for diagnosis of, 404
transcript detection in diagnosis of, 405,
407
transmission of, 400
treatment for, 403
viral load interpretations with diagnosis
of, 402
virus isolation for diagnosis of, 404, 407
Human herpes virus 6A (HHV-6A), 5
Human herpes virus 6B (HHV-6B), 5
Human herpes virus 7 (HHV-7), 399
antibody tests in diagnosis for, 405–406
biology of, 400
clinical aspects of, 402
diagnostic best practices for, 408
discovery of, 400
epidemiology of, 400–401
laboratory diagnosis for, 405–406
prevention of, 403
taxonomy and characterization of, 5
transmission of, 400–401
treatment for, 403
Human herpes virus 8 (HHV-8), 399
biology of, 400
blood transfusion with, 401
clinical aspects of, 402–403
diagnostic best practices for, 408
discovery of, 400
enzyme-linked immunosorbent assays in
diagnosis of, 406
epidemiology of, 401
immunofluorescence assays in diagnosis
of, 406
Immunohistochemistry in diagnosis of,
406–407
Kaposi's sarcoma associated with,
402–403
laboratory diagnosis for, 406–407, 408
organ transplantation with, 401
PCR in diagnosis of, 407
prevention of, 403
serology for diagnosis of, 406, 408
In Situ hybridization in diagnosis of,
406–407
taxonomy and characterization of, 5
transmission of, 401
treatment for, 403
Human immunodeficiency virus (HIV), 14
Alere Q NAT system for, 248
antibody detection assays for, 233–235
antiviral susceptibility testing for,
221–222
best practices for, 540–541
biomarker detection assay for, 248
biology of, 527–529
clinical significance of, 530–531
coreceptor tropism determination with,
537
cytomegalovirus infection with, 381
database websites for, 17
detection and diagnosis of, 532–538
alternative specimens, 535–536
confirmation of, 536
in infants and children, 535
principal questions for, 533–538
rapid tests, 535–536
virus properties in, 536–537
when to test after exposure, 534–535
dried blood spot testing for, 248–249
epidemiology of, 529
future technology for, 248–249
genetic marker in predicting outcome of,
574
global distribution of, 529
HLA gene polymorphisms' effect on,
574
origin of, 527
preferred procedure for testing of, 540
prevention of transmission of, 532
public health laboratory testing for,
589–590
quantitative detection of, 145–146,
155–156
repeat specimen collection for, 71–72
replication characteristics of, 528
retroviral replication for, 527–528
screening in, 534
serologic detection for, 105
specimen information for congenital
infections with, 68
specimen information for infections with
joint pain with, 64
specimen information for infectious
mononucleosis with, 69
specimen information for retroviruses
with, 66
transmission, 529
treatment for, 531–532
Human immunodeficiency virus (HIV), 14 (continued)
  viral classification of, 527–529
  viral load with, 537–538
  virologic and immunologic parameters for infection of, 530
  virus diversity for, 527–528
  window periods in early infection of, 534
Human mastadenovirus
  renaming of, 15
  taxonomy and characterization of, 5
Human metapneumovirus (HMPV)
  best practices for, 271
  biology of, 257–258
  classification of, 257–258
  clinical significance of, 263
  diagnosis of, 268
  epidemiology of, 260
  pneumonia, 13
  prevention of, 265–266
  relative importance of, 257–258, 260
  specimen information for respiratory disease with, 60
  taxonomy and characterization of, 13
  treatment of, 265–266
Human papillomavirus (HPV)
  best practices for, 421–422
  biology of, 413–414
  classification of, 413–414
  clinical significance of, 415
  cutaneous, 415–416
  cytological screening for, 60
  detection and diagnosis of, 418–421
  diseases associated to, 415
  DNA-based assays for identification of amplification-based assays, 420
  antigen detection, 421
  genotyping, 420–421
  serology, 421
  signal amplification, 419–420
  epidemiology of, 414–415
  FDA-approved assays for high-risk HPV testing, 419
  mucosal, 416–417
  prevention of, 417–418
  public health laboratory testing for, 590
  specimen collection for, 419
  specimen information for genital infections with, 66
  treatment of, 417–418
  vaccines comparison for, 418
  viral proteins functions with, 414
Human parainfluenza virus, 12–13
Human parvovirus, 9
Human picornaviruses, taxonomy and characterization of, 7
Human polyomaviruses
  best practices for, 436–438
  biology of, 427–428
  clinical significance of, 431–433
  detection and diagnosis of, 433–436
  epidemiology of, 428–431
  genome organization for, 427
  life cycle of, 427–428
  molecular epidemiology of, 429–431
  prevention of, 433
  seroepidemiology of, 428–429
  structure of, 427
  treatment for, 433
  viral classification of, 427–428
Human polyomaviruses 6, 427
  clinical significance of, 433
  diagnosis of, 436
  seroprevalence of, 430
Human polyomaviruses 7, 427
  clinical significance of, 433
  diagnosis of, 436
  seroprevalence of, 430
Human polyomaviruses 9, 427
  clinical significance of, 433
  diagnosis of, 436
  seroprevalence of, 430
Human polyomaviruses 12, 427
  clinical significance of, 433
  diagnosis of, 436
  seroprevalence of, 430
Human respiratory syncytial virus
Human T-lymphotropic viruses (HTLV)
  best practices for, 540–541
  biology of, 527–529
  clinical significance of, 531
  confirmation tests for, 538–540
  detection and diagnosis of, 538–540
  ELISA tests for, 539
  epidemiology of, 529–530
  global distribution of, 529–530
  origin of, 527
  prevention of, 532
  primate, 14
  proviral load with, 540
  replication characteristics of, 528–529
  retroviral replication for, 527–528
  screening tests for, 538
  specimen information for exanthems with, 61
  specimen information for neurological infections with, 63
  specimen information for retroviruses with, 66
  transmission, 530
  treatment for, 532
  viral classification of, 527–529
  virus diversity for, 527–528
  western blot tests for, 538–539
Human torovirus, 8, 20
  Human virome, 561
  Human torovirus, 8, 20
  Human virome, 561
  ICD. See International Statistical Classification of Diseases and Related Health Problems
  ICTV. See International Committee on Taxonomy of Viruses
  IF. See Immunofluorescence
  IFA. See Immunofluorescence antibody assay
  IgM anti-Hbc, hepatitis B virus detection with, 348
  IgM assay, measles virus diagnosis with, 299
  IHC. See Immunohistochemistry
  ILAC. See International Laboratory Accreditation Cooperation
  Illumigene® HSV 1&2, 138, 140
  Illumina sequencing technology, 176
  Immunoblot. See also Enzyme immunoassay
  astroviruses diagnosis with, 319
  BD Veritor System Flu A+B, 246–247
caliciviruses diagnosis with, 317
tenteric adenovirus diagnosis with, 319–320
  microsphere, 506
  rotavirus diagnosis with, 318
  Sofia Influenza A+B Fluorescent, 246
  Immunochromatography (Lateral Flow), 96–98
  characteristics of, 101
  quality assurance for, 102
  Immunofluorescence (FA), 95–96
  application of, 109
  characteristics of, 101
direct methods of, 95, 96, 101, 481–483, 551–552
  FDA approval of, 95
  indirect methods of, 95–96, 101
  limitations of, 109
  method for, 108–109
  quality assurance for, 102, 109
  staining using, 81
  troubleshooting for, 109
  Immunofluorescence antibody assay (IFA), direct, 32
  HHV-8 diagnosis with, 406
direct, 95–96
  characteristics of, 101
  measles virus diagnosis with, 299
  Immunoglobulin M determinations
  application of, 111–112
  method for, 111
  quality assurance for, 112–113
  troubleshooting for, 112–113
  Immunohistochemistry (IHC)
  HHV-8 diagnosis with, 406–407
  staining, 98–100
  Immunostaining
  blind, 83
cell culture, 83
  IF staining, 81
  Incubation of cell cultures, 80–81
times for enteroviruses, 281
times for parechoviruses, 281
  Indel, 174
  Indiana virus, 13
  Infections with joint pain, specimen information for, 64
  Infectious mononucleosis
cytomegalovirus with, 380
  EBV with, 388, 391, 393–394
  specimen information for, 69
  Inflammasome defects, 571
Isfahan virus

ISO. See In Situ hybridization

ISO. See International Organization for Standardization

Isfahan virus

ISO. See International Organization for Standardization

Isothermal nucleic acid amplification methods, 137–143

future aspects of, 141–142

future perspectives on, 142–143

loop-mediated, 139–140

nicking endonuclease amplification reaction, 140

present state of, 141–142

recombinase polymerase, 140–141

strand displacement, 139

strengths of, 141

transcription-based, 137–139

weaknesses of, 141

J

Japanese encephalitis virus, 9, 496

clinical significance of, 501

epidemiology of, 499

JC polyomavirus (JCPyV), 427

clinical significance of, 431

diagnosis of, 435

progressive multifocal leuкоencephalopathy associated with, 438

PVAN associated with, 438

seroprevalence of, 428–429, 430

JC virus

specimen collection for, 69

specimen information for neurological infections with, 63

specimen information for ocular infections with, 70

The Joint Commission (TJC), 36–37

Jungle yellow fever, 19

Junin hemorrhagic fever, 11, 19

Junin virus, 11

K

Kaposi's sarcoma associated herpes virus (KSHSV)

HHV-8 associated with, 402–403

taxonomy and characterization of, 5

KFDV. See Kyasanur forest disease virus

KHSV. See Kaposi's sarcoma associated herpes virus

KingFisher, 123

KingFisher Flex, 123

KingFisher ML, 123

KI polyomavirus (KIPyV), 427

clinical significance of, 432

diagnosis of, 435–436

seroprevalence of, 430

Komer, 174

Kohus, 9

Koch's postulates, 20

kPCR, 149

Kyasanur forest disease virus (KFDV), 9, 19, 496

L

Laboratories
certificate of compliance for, 36

regulation of testing in, 35–36

staff competency and requirements for, 27–28

test selection's importance in, 59–60

Laboratory accreditation programs (LAPs), 39

Laboratory design, 51–55

bidding for, 52

biosafety cabinet in, 53

biosafety level requirements in, 52

CDC guidance for, 54

clinical virology elements needed in, 53–54

construction phase of, 52

LEAN concepts for, 55

occupancy phase of, 52–53

phases of, 51–53

planning for, 51

requirements for, 51

schematic for, 53, 54

workflow in, 54–55

Laboratory developed procedures (LDP), 153

Laboratory safety, 41–48

biosafety in, 44–46

principles of, 41

bleach in, 44

BSL levels in, 44–46

recommended practices for, 45

chemical safety, 43–44

culture of safety in, 41–42

disinfection in, 42–43

DMSO in, 44

electrical safety, 44

erthidium bromide in, 43–44

fire safety, 44

guanidinium compounds in, 43

hazard exposure with, 42

HEPA filter in, 45

personal protective equipment in, 45

risk assessment for, 42

safe transport of specimens in, 47–48

Safety Data Sheets for, 43

sterilization in, 42–43

waste disposal in, 48

work practices with, 42, 45, 46–47

La Crosse encephalitis. See California encephalitis

La Crosse virus, 497

clinical significance of, 501

LAMP. See Loop-mediated isothermal amplification

Langat virus, 9

LAPs. See Laboratory accreditation programs

Lassa fever, 19

Lassa virus

specimen information for hemorrhagic fevers with, 70

taxonomy and characterization of, 11

Lateral Flow. See Immunochromatography

LDP. See Laboratory developed procedures

Lemboko virus, 7

Leishmania, 14

Leukoplakia, 415

L.H.T. (Lwoff Horne Tournier) system, 14

Life Technologies SOLiD system, 175

Locked nucleic acid (LNA), 147

Loop-mediated isothermal amplification (LAMP)

advantages of, 141

application of, 140

commercially available kits for, 138

disadvantages of, 141

strengths of, 141

technique for, 139–140

weaknesses of, 141

Loaing ill virus, 9

Lujo virus, 11

Lwoff Horne Tournier. See L.H.T. system

Lymphocryptovirus, 5
Lymphoproliferative diseases, 388

Lyssavirus

Macacine herpesvirus

M2000 sp, 123, 124

Machupo hemorrhagic fever, 11, 19

Maculopapular rash, enteroviruses with, 63

Lymphomas

Lymphocytic choriomeningitis virus

Major groove binding (MGB), 147

Magnapure Compact, 123

Magnapure, 123

Maculopapular rash, enteroviruses with, 283

Madanani virus, 10, 16

Madrid virus, 11

Magnapure, 123

Mignapure Compact, 123

Major groove binding (MGB), 147

Malawi polyomavirus (MWPyV), 427

clinical significance of, 433
diagnosis of, 436

MALT-TOE See Matrix assisted laser/desorption ionization time of flight

Mammalivirus, 9

Mammalian orthoreovirus

Marburg marburgvirus, 12

Marburg virus
disease, 12, 19

specimen information for hemorrhagic fevers with, 70
taxonomy and characterization of, 12

Massively parallel pyrosequencing, 179

Mastadenovirus

renaming of, 15
taxonomy and characterization of, 5

Mate pair read, 174

Matrix assisted laser/desorption ionization time of flight (MALT-TOF), 134–135

Maxwell, 123

Mayaro virus (MAYV), 494
taxonomy and characterization of, 10

MCPyV. See Merkel cell polyomavirus

Measles virus, 12

best practices for, 304

biology of, 293
clinical significance of, 295–296
detection/diagnosis of, 298–301
epidemiology of, 294

gIgM assay for, 299

immunofluorescence antibody assay for, 299

plaque-reduction neutralization assay for, 299

prevention of, 297

serological results for, 300
treatment for, 297

Vero/hSLAM cell line for, 300

viral classification of, 293

Membrane EIA, 98, 99

c characteristics of, 101

Meridian Bioscience, 138, 140

Merkel cell polyomavirus (MCPyV), 427

clinical significance of, 432
diagnosis of, 436

seroprevalence of, 430

MERS. See Middle East respiratory syndrome

Metagenomics, 174

Metapneumovirus, 13

MGD. See Major groove binding

MIA. See Microsphere immunoassays

Microarray technology, arboviruses with, 507

Microsphere immunoassays (MIAs), 506

MicroWell-based EIA, 99–100

characteristics of, 101

Middle Eastern respiratory syndrome coronavirus, 8

Middle East respiratory syndrome (MERS), 83

cautions in handling specimens from, 73

DNA sequencing for, 192

public health laboratory testing for coronavirus, 592

specimen information for respiratory disease with, 60

MiniON, 179

MiSeq, 178, 179

MMLV. See Moloney murine leukemia virus

Molecular beacon, 132

Molecular phylogenetics, 19–20

Molecular testing, 31

Molluscipoxvirus, 5

Molluscipoxvirus molluscum contagiosum virus, 459

clinical signs, symptoms, and severity for, 462–463
diagnoses of, 462–463
differential diagnoses for, 463
electron micrograph of thin section of, 460

epidemiology of, 462

historic standards for diagnosis of, 458

incidence of, 462

pathogenesis of, 462

prevalence of, 462

transmission of, 462

Molluscus contagiosus virus

specimen information for exanthems with, 61
taxonomy and characterization of, 5

Moloney murine leukemia virus (MMLV), 130

Monkeypox virus, 459

historic standards for diagnosis of, 458
taxonomy and characterization of, 5

Mollivirus, 12

Mucosal HPV

cervical cancer, 416–417

genital warts, 416

oropharyngeal cancer, 416

respiratory papilloma, 416

Multiple sclerosis

EBV associated with, 391

HHV-6 associated with, 401

Multiplexed run, 174

Multiplex PCR, 133–134

Mumps virus

best practices for, 304–305

biology of, 293

clinical significance of, 296–297
detection/diagnosis of, 301
epidemiology of, 294–295

prevention of, 297–298

serological results for, 302

specimen information for neurological infections with, 63

specimen information for respiratory disease with, 60
taxonomy and characterization of, 13
treatment for, 297–298

viral classification of, 293

Mapapillomavirus, 1

Murray Valley encephalitis virus (MVEV), 496
epidemiology of, 499
taxonomy and characterization of, 9

MWPyV. See Malawi polyomavirus

Myasthenia gravis, EBV associated with, 391

Myelitis, 14

N

NAAT. See Nucleic acid amplification testing

NAI. See Neuraminidase inhibitors

Nairovirus, 11

NASBA. See Nucleic acid sequence-based amplification

Nasopharyngeal carcinoma, EBV associated with, 390, 392, 396

NAT. See Nucleic acid testing

National Center for Biotechnology Information (NCBI), 173

National Reference Laboratories (NRLs) countries offering services for, 596–606

virology services of, 595–606

NEAR. See Nicking endonuclease amplification reaction

Neonatal enterovirus diseases, 284

Nephropathy, BK polyomavirus associated, 437–438

Nested PCR, 130–131

Neuraminidase inhibitors (NAI), influenza virus treatment with, 206

Neurological infections, specimen information for, 62–63

Neutralization

application of, 106

methods for, 106

quality assurance for, 107

troubleshooting for, 107

New Jersey polyomavirus (NJPyV-2013), 427

c clinical significance of, 433
diagnosis of, 436

New Jersey virus, 13

New York virus, 11

Next generation sequencing (NGS)
arboviruses diagnosis with, 307

bridge amplification in, 175–176

as future technology, 243–244

gastrointestinal virus diagnosis with, 320

host contamination with, 180–181

human virome with, 561

implementation options for, 178

second generation, 175–176

sequencing increase from, 173

strategies for, 179–180

technologies and platforms for, 179

terminology for, 174

third generation, 176–177

workflows for, 175–178

NextSeq, 179

NGS. See Next generation sequencing

Nicking endonuclease amplification reaction (NEAR)
advantages of, 142
application of, 140
commercially available kits for, 138
disadvantages of, 142
strengths of, 141
technique for, 140
weaknesses of, 141

Norah virus
biology of, 515–516
clinical significance of, 518
detection and diagnosis of, 520
diagnostic best practices for, 522
epidemiology of, 517
prevention of, 519
taxonomy and characterization of, 12
treatment for, 519
viral classification of, 515–516
NJPyV-2013. See New Jersey polyomavirus
Norovirus
antigen detection assays for, 231–232
public health laboratory testing for, 380–591
specimen information for gastroenteritis with, 65
taxonomy and characterization of, 9
taxonomy determination for, 22

Norswalk virus, 9

NRLs. See National Reference Laboratories

Nucleic acid amplification testing (NAAT) 31
Chlamydia pneumoniae diagnosis with, 553
Chlamydia trachomatis diagnosis with, 550–551
cytomegalovirus diagnosis with, 377
for herpes simplex virus, 368–369
for varicella-zoster virus, 369
Nucleic acid-based molecular methods, 119
Nucleic acid detection assays enterovirus in, 235
gastrointestinal viruses in, 236
hepatitis B virus detection with, 348
HHV-6 diagnosis with, 404, 407
respiratory viruses in, 235–236
Nucleic acid extraction automated methods for, 119–126
in-answer out, 122–123
PCR mix setup function with, 124
performance of, 123–125
setup of master and reaction mix with, 121–122
automation of manual processes for, 121
everging technology for, 125–126
guanidinium thiocyanate-phenol-chloroform extraction for, 117–118

Nucleic acid sequence-based amplification (NASBA)
advantages of, 141–142
application of, 137–138
commercially available kits for, 138
disadvantages of, 141–142
quantitative molecular methods with, strengths of, 141
weaknesses of, 141
Nucleic acid testing (NAT) 137
cytomegalovirus diagnosis with, 378–379
Nucleoside analogue (3TC), hepatitis B virus treatment with, 344
NucliSENS easyQ 137, 138
NucliSens miniMAG system, 119

NucliSens miniMAG system, 119

O

Occupational Safety and Health Administration (OSHA)
Bloodborne Pathogen Standard of, 44, 47

Ocular infections, specimen information for, 70

Omsk hemorrhagic fever virus (OHFV), 9, 496

O'O Hung Nyong virus (ONNV), 494

Oncology, 590

Oral cavity cancer, 415
Oral hairy leukoplakia, EBV associated
Oral lichen planus, 415
Oral squamous cell papilloma, 415
Orbitus, 7
Orf virus, 459
taxonomy and characterization of, 6
Organ transplantation. See also Posttransplant lymphoproliferative disorder
cytomegalovirus infection in recipients of, 381–382
human herpes virus 8 with, 401
Oropharyngeal cancer, 416
Oropharyngeal squamous cell carcinoma,
Orotopuche virus, 11
Orthohantavirus, 11
Orthopoxviruses, 5, 458–461
Orthoreovirus, 7
Ongoro virus, 7
OSHA. See Occupational Safety and Health Administration

Ovation RNA-Seq kit, 175

P
PacBio RS, 179
Paired-end read, 174
PAMPs. See Pathogen-associated molecular patterns

Papillomaviridae, 18
Papillomaviruses, 21
Parainfluenza virus (PIV)
best practices for, 271
biology of, 258
classification of, 258
clinical significance of, 263
diagnosis of, 268
cell culture, 81–82, 88
epidemiology of, 260–261

human, 12–13
pneumonia, 12
prevention of, 266
relative importance of, 258, 260–261
specimen information for respiratory disease with, 60
taxonomy and characterization of human, 12–13
treatment of, 266

Paralytic myelitis, enteroviruses with, 282
Parapoxviruses
clinical signs, symptoms, and severity for, 462–463
dermis during infection from, 463
diagnoses of, 464
differential diagnoses for, 464
epidemiology of, 463–464
dermis during infection from, 463
gastrointestinal viral association less common with, 451
gastrointestinal viral association less common with, 451
geographical distribution of, 463
historic standards for diagnosis of, 458
incidence of, 463–464
lesion histopathology for, 463
pathogenesis of, 463
prevalence of, 463–464
taxonomy and characterization of, 6
transmission of, 463

Parechoviruses, 277–287
age in risk for, 280–281
antigenicity of, 19, 496
antivirals in treatment of, 284
asymptomatic infections with, 281–284
biology of, 277–279
classification of, 277–279
clinical syndromes with, 281–284
diagnostic best practices for, 287
epidemiology of, 279–281
epidemiology factors with, 280–281
history of discovery for, 277–278
incubation times for, 281
laboratory diagnosis of, 284–287
methods for detection of, 285
mode of transmission for, 279–280
molecular detection and characterization for, 285–286
molecular variation with, 281
neutralization of, 279
pathogenesis with, 281–284
replication in cell culture of, 279
risk factors for, 280–281
seasonal factors with, 280–281
sex in risk for, 280–281
socioeconomic factors with, 280–281
structure of, 278–279
taxonomy and characterization of, 9
treatment and prevention of, 284
virus isolation and identification for, 285

Parvovirus B19, 443
associations less common with, 451
commercial molecular assays for detection of, 449
diagnosis of, 448–450
specimen information for congenital infections with, 68
specimen information for exanthems with, 61
specimen information for infections with joint pain with, 61
specimen information for ocular infections with, 70

Parvoviruses
best practices for, 450
biology of, 443–444
Paroviruses (continued)
clinical significance of, 446–447
detection and diagnosis of, 447–450
epidemiology of, 444–446
fetal hydrops with, 451
infection in immunocompromised
patients with, 451
molecular characteristics of, 443–444
during pregnancy, 451
prevention of, 447
transient aplastic crisis with, 451
treatment for, 447
viral classification of, 443–444
Pathogen-associated molecular patterns
(PAMPs), 568
Pathogen recognition receptors
(PPRs), 567
PCR. See Polymerase chain reaction
PCR-ESI/MALDI, 134–135
PCR/ESI-MS. See Polymerase chain
reaction/Electrospray ionization
mass spectrometry
Penile cancer, 415
Pericarditis, enteroviruses with, 283
Personal protective equipment (PPE), 45
Peritoneal dialysis
Pneumovirus
Pleurodynia, enteroviruses with, 283
Picornaviruses
Picobirnaviruses, 320
Pleurodynia
Point-of-care test (POCT), 279
Poliovirus
Polyomavirus
Polyomavirus genome organization for,
427
life cycle of, 427–428
phylogenetic tree of, 428
taxonomy and characterization of, 6
Posttransplant lymphoproliferative
disease
Polyomaviruses
Poliovirus
cytopathic effect with, 277–278
Poliovirus, cytopathic effect with, 277–278
Polymerase chain reaction (PCR), 31, 59,
137
analyte specific reagents with, 133
antiviral susceptibility testing with, 202
conventional, 129–130, 134
digital, 134, 135, 145, 149, 244–245
emerging techniques for, 134–135
enteric adenoviruses diagnosis with, 320
ESI/MALDI, 134–135
ESI-MS, 245
exanthems information with, 61
gastroenteritis information with, 65
HHV-6 diagnosis with, 404, 407
HHV-8 diagnosis with, 407
infections with joint pain information
with, 64
influenza virus screening with, 208
kPCR, 149
multiplex, 133–134
nested, 130–131
neurological infections information with,
62–70
nucleic acid amplification by, 129–135
quantitative, 145, 146–149, 404, 407
real-time detection of nucleic acids by,
131–134, 137
enteric adenoviruses diagnosis with, 320
quantitative molecular methods with,
133
reverse transcription, 137, 317–319
Taq with, 129
techniques comparison for, 134
Polymerase chain reaction/Electrospray
ionization mass spectrometry (PCR/
ESI-MS), 245
Polyomaviruses
PTLD. See Posttransplant lymphoproliferative
disease
Public health laboratory (PHL)
Public health laboratory (PHL)
role of, 585
scope of services by, 585–592
submitting specimens to, 592–593
testing performed by
arbovirus surveillance, 585–589
chikungunya, 592
Dengue virus, 592
hepatitis B and C viruses testing, 589
HIV testing, 589–590
human papillomavirus testing, 590
influenza virus testing, 590
middle east respiratory syndrome
coronavirus, 592
norovirus testing, 590–591
poxviruses testing, 591
rabies virus testing, 591
respiratory viruses testing, 590
vaccine-preventable diseases, 591–592
virology services of, 585–593
Pyamali virus, 11
PVAN, JCPyV associated with, 438
Q
QIAamp DNA Mini and Blood Mini Kit,
118–119
QIAamp DNA Mini Kit, 118–119
QIAamp Viral RNA Mini Kit, 118
qPCR. See Real-time PCR
qRT-PCR. See Real-time RT-PCR
Quality assurance, 27–34
bioinformatics, 186–188
cell cultures, 31, 88–89
corrective and preventive action in, 33
direct antigen detection, 31–32
documentation for, 28
enzyme immunoassay, 102, 111
hemagglutination inhibition, 107–108
immunochromatography, 102
immunofluorescence, 102, 109
immunoglobulin M determinations, 112–113
importance, 27
instrumentation, 32
materials, 31
molecular testing, 31
neutralization, 107
point-of-care test, 236–237
procedure manual, 28–30
proficiency testing, 32–33
quality control and standards in, 32
requirements, 31
regulatory requirements, 27
specimen collection and transport, 30–31
staff competency, 27–28
test verification and validation in, 33–34
viral antigen detection, 102–103
viral isolation, 88–89
viral serology, 31–32
virology, 27
western blot, 113
Quality control, 32
Quality trimming, 174
Quantitative-mediated isothermal amplification (Q-LAMP)
advantages of, 142
application of, 140
commercially available kits for, 138
disadvantages of, 142
strengths of, 141
technique for, 139–140
weaknesses of, 141
Quantitative molecular methods (Viral loads), 145–160
applications of, 155–159
assessment of, 149–155
for BK virus, 159
for CMV, 145–146, 157–158
digital PCR used in, 145, 149
for Epstein-Barr Virus, 145, 158
FDA-approved, 145–146
future implications of, 159–160
for Hepatitis B, 146, 157
for Hepatitis C, 146, 156–157
for HIV, 145–146, 155–156
kPCR used in, 149
laboratory developed procedures for, 153
limitations of, 149–153
NASBA used in, 147–149
PCR used in, 145, 146–149
performance of, 149–155
quantification of, 149–150
real-time PCR methods used in, 147
sigma metrics for precision and accuracy in, 153–155
specimen integrity with, 151–152
standardization in, 152–153
variability of, 150–151
QuickGene 810, 123
Qx Amplified DNA Assays, 138
R
coronaviruses diagnosis with, 39
infections with, 63
specimen information for neurological infections with, 63
Resiprovirus, 12
Respirovirus, 12
Retrovirus, 15
ResoGene, 242
Resolvy, 242
Respiratory syncytial virus (RSV), 13
antigen detection assays for, 230–231
best practices for, 271
biological of, 257–258
classification of, 257–258
clinical significance of, 263
diagnosis of, 268
diagnosis of infections, cell culture, 88
epidemiology of, 260
pneumonia, 13
prevention of, 265–266
relative importance of, 257–258, 260
specimen information for respiratory disease with, 60
taxonomy and characterization of, 13
treatment of, 265–266
Respiratory viruses
adenovirus, 21–22, 60, 61, 65, 70, 87, 259, 262, 264–265, 267, 269–270, 272
antigen detection assays for, 229–231
genetic marker in predicting outcome of, 574–575
human coronaviruses, 8, 258–259, 261–262, 264, 266–267, 269, 271
human metapneumovirus, 13, 60, 257–258, 260, 262, 263, 265–266, 268, 271
nucleic acid detection assays for, 235–236
parainfluenza virus, 12–13, 60, 81–82, 88, 258, 260–262, 263, 266, 268, 271
public health laboratory testing for, 590
rhinovirus, 9, 60, 88, 258, 261, 262, 263–264, 266, 268–269, 271
respiratory syncytial virus (RSV), 13
antigen detection assays for, 230–231
best practices for, 271
biological of, 257–258
classification of, 257–258
clinical significance of, 263
diagnosis of, 268
diagnosis of infections, cell culture, 88
epidemiology of, 260
pneumonia, 13
prevention of, 265–266
relative importance of, 257–258, 260
specimen information for respiratory disease with, 60
taxonomy and characterization of, 13
treatment of, 265–266
Regulatory compliance, 35–39
agencies involved in, 35
CAP in, 36–37
CLIA in, 36–37
ISO standards in, 37–39
test complexity with, 35–36
TJC in, 36–37
Renal infections, specimen information for, 70
Rescue, Alarm, Contain, and Extinguish. See Race
Resequencing, 174
Resistance testing
antiviral susceptibility in, 203–204
HCV detection with, 357
Respiratory disease. See also Respiratory viruses
enteroviruses with, 284
specimen information for respiratory disease with, 60
Respiratory papilloma, 416
Respiratory syncytial virus (RSV), 13
antigen detection assays for, 230–231
best practices for, 271
biological of, 257–258
classification of, 257–258
clinical significance of, 263
diagnosis of, 268
diagnosis of infections, cell culture, 88
epidemiology of, 260
pneumonia, 13
prevention of, 265–266
relative importance of, 257–258, 260
specimen information for respiratory disease with, 60
taxonomy and characterization of, 13
treatment of, 265–266
Respiratory viruses
adenovirus, 21–22, 60, 61, 65, 70, 87, 259, 262, 264–265, 267, 269–270, 272
antigen detection assays for, 229–231
genetic marker in predicting outcome of, 574–575
human coronaviruses, 8, 258–259, 261–262, 264, 266–267, 269, 271
human metapneumovirus, 13, 60, 257–258, 260, 262, 263, 265–266, 268, 271
nucleic acid detection assays for, 235–236
parainfluenza virus, 12–13, 60, 81–82, 88, 258, 260–262, 263, 266, 268, 271
public health laboratory testing for, 590
rhinovirus, 9, 60, 88, 258, 261, 262, 263–264, 266, 268–269, 271
Resiprovirus, 12
Reston ebolavirus, 12
Retinoic acid-inducible gene 1 (RIG-1), 568
Retroviruses, specimen information for, 66
Reverse transcription qPCR (RT-PCR), 137
arboviruses diagnosis with, 506
astroviruses diagnosis with, 319
Reverse transcription qPCR (RT-PCR), 137 (continued)
calcivirus diagnosis with, 317
HHV-6 diagnosis with, 404, 407
Rotavirus diagnosis with, 318
Rhabdovirus, 5
Rheumatoid arthritis, EBV associated with, 86
Rhinovirus (RVH) best practices for, 271
biology of, 258
classification of, 258
clinical significance of, 263–264
diagnosis of, 268–269
diagnosis of infections, cell culture for, 88
epidemiology of, 261
prevention of, 266
relative importance of, 258, 261
specimen information for respiratory disease with, 60
taxonomy and characterization of, 9
treatment of, 266
Rift Valley fever, 19, 497
RNA detection assays, HCV detection with, 355–357
Roche Cobas Liat System, 247
Rosavirus, 5
Ross River virus (RRV), 494
Rubivirus, 10
rabies virus, 13
RVB. See Rotavirus B
RVC. See Rotavirus C
RVH. See Rotavirus H
Rubella virus best practices for, 305
biology of, 293–294
clinical significance of, 297
detection/diagnosis of, 301–304
epidemiology of, 295
prevention of, 298
serological results for, 303
treatment for, 298
viral classification of, 293–294
Rusubivirus, 8
Sahtá virus, 11
Safety Data Sheets, 43
Salivivirus, 9
SAM/BAM, 174, 181
Sandfly fever Naples virus, 497
taxonomy and characterization of, 12
Sangassou virus, 16
Sanger sequencing, 173–175
Sapovirus
specimen information for gastroenteritis with, 63
taxonomy and characterization of, 9
Sapporo virus, 9
SARS. See Severe acute respiratory syndrome
Scalable target analysis routine (STAR), 147
Scorpion molecules, 132
SDA. See Strand displacement amplification
Seadomavirus, 7
Sealbox virus, 459
Semliki Forest virus
Severe acute respiratory syndrome (SARS), 8, 83
care and handling of specimens from, 73
DNA sequencing for, 192
specimen information for respiratory disease with, 60
Severe fever and thrombocytopenia syndrome
Severe fever with thrombocytopenia syndrome virus (SFTSV), 497
epidemiology of, 500
SFTS. See Severe fever and thrombocytopenia syndrome
SFTSV. See Severe fever with thrombocytopenia syndrome
SVF. See Semliki Forest virus
shell vial (centrifugation) technique, 83–86
cytomegalovirus diagnosis with, 376, 378
description of, 83–84
inoculation of, 84
reading procedure for, 84
sensitivity of, 83
test procedure for, 84
Sigma metrics, quantitative molecular methods assessed with, 153–155
Signal amplification methods
advantages of, 167
branch DNA technology application in virology laboratory of, 170
characteristics of, 168–170
principles of, 168–170
scheme for, 169
challenge from target amplification methods, 147
comparison of technologies, 170
HPV identification with, 421
hybrid capture technology application in virology laboratory of, 168
characteristics of, 167–168
principles of, 167–168
scheme for, 168
Simplexvirus, 5
Sindbis virus (SINV), 494
clinical significance of, 500
epidemiology of, 498
taxonomy and characterization of, 10
Single-molecule, real-time (SMRT) technology, 176
Single nucleotide polymorphisms (SNPs), 568
SINV. See Sindbis virus
Sixth disease. See Exanthema subitum
Sjogren’s syndrome, EBV associated with, 391
Skanktpox virus, 459
SLEV. See Severe fever with thrombocytopenia syndrome
Smallpox, taxonomy and characterization of, 5
Smooth muscle tumors, EBV associated with, 391, 392, 396
SMRT technology. See Single-molecule, real-time technology
SNP analysis, 174
SNPs. See Single nucleotide polymorphisms
Soja influenza A+B Fluorescent Immunassay, 246
Specimen collection, 59–74
for congenital infections, 67–68
for exanthems, 61
future considerations for, 73–74
for genital infections, 66
for heart infections, 70
for hemorrhagic fevers, 70
host factors that affect, 60–66
importance of, 59–60
for infections with joint pain, 64
for infectious mononucleosis, 69
for neurological infections, 62–63
for ocular infections, 70
quality assurance for, 30–31, 71
for renal infections, 70
repeat, 71–72
for respiratory disease, 60
for retroviruses, 66
safety in, 47–48
test platform importance for, 66, 69, 71
test results interpretation with proper, 59
viral factors that affect, 66
Specimen processing, 72
Specimen selection, importance for, 59–60
Specimen storage, 72–73
Specimen transport, 59–74
quality assurance for, 30–31
transportation time in, 72–73
transport medium in, 72–73
Specimen type, 71
SPR. See Surface Plasmon Resonance
Staff, competency and requirements for,
STAR. See Scalable target analysis routine
Sterilization
chemical methods of, 43
laboratory safety with, 42–43
physical methods of, 43
St. Louis encephalitis virus (SLEV), 9, 496
specimen collection for, 69
specimen information for neurological
infections with, 62
St. Louis poliovirus (SLTpyV), 427, 433
diagnosis of, 436
Strand displacement amplification (SDA), 31
advantages of, 142
application of, 139
commercially available kits for, 138
disadvantages of, 142
strengths of, 141
technique for, 139
weaknesses of, 141
Sudan ebolavirus, 12
Super E-mix, 85–86
Surface Plasmon Resonance (SPR), 245–246
Sylvatic yellow fever, 19
Systematic error, 174
Systemic lupus erythematosus, EBV
associated with, 391
Systemic sclerosis, EBV associated with, 391
T
Tacaiuma virus, 11
Tai forest ebolavirus, 12
Tanapox virus, 459
taxonomy and characterization of, 6
Taq. See Thermo aquaticus
TaqMan probes, 131–132
TaqMan reporter oligonucleotides, 131
TAT. See Transfusion-associated
transmission
Tetrapox virus, 459
Taxonomy databases websites, 17
Test complexity
CLIA 88 in regulation of, 35–36
determination of, 36
FDA approval of, 35–36
Test selection, 59–60
Test verification, quality assurance with, 33–34
Tetraoviruses, 444
clinical significance of, 447
epidemiology of, 445
taxonomy and characterization of, 7
Thelovirus, 8
Thermus aquaticus (Taq), PCR from, 129
Tohutukavirus, 11
3M Integrated Cycler, 124
3TC. See Nucleoside analogue
tick-borne encephalitis virus, 9, 496
epidemiology of, 499
Tigris 180, 124
TJC. See The Joint Commission
TOR-2. See Transfusion-mediated
amplification
Togaviridae, 493–495
clinical significance of, 500
family summarized, 494
Toll-like receptors
Transplant recipients.
Transient aplastic crisis, 451
Transfusion-associated transmission (TAT), 59–60
Transfusion-related polycythemia vera
Trichomonas vaginalis
Torque teno virus (TTV), 7, 563
Torque teno mini virus (TTMV), 563
Torque teno midi virus (TTMDV), 563
Toscana virus, 497
Total anti-HBc, hepatitis B virus detection
with, 348
Transcription mediated amplification
(TMA), 31, 137–139
advantages of, 141–142
application of, 138–139
commercially available kits for, 138
disadvantages of, 141–142
strengths of, 141
weaknesses of, 141
Transfusion-associated transmission (TAT), 71
for arboviruses, 507
Transient aplastic crisis, 451
Transplant recipients. See also
Posttransplant lymphoproliferative
disorder
cytomegalovirus infection with, 381–382
human herpes virus 8 with, 401
Trichodoypusila spinulosa-associated
polymavirus (TSPyV), 427
clinical significance of, 432–433
diagnosis of, 436
seroprevalence of, 430
TriTip technology, 119, 120
TPyV. See Trichodoypusila spinulosa-
associated polymavirus
TTMDV. See Torque teno midi virus
TTMV. See Torque teno mini virus
TTV. See Torque teno virus
Tube culture, cytomegalovirus diagnosis
with, 376
Tumor virus, 459
Yaba monkey, 6
United States Preventive Services Task
Force (USPSTF), cervical cancer
screening by, 413
Urban yellow fever, 19
U.S. Environmental Protection Agency
(EPA), disinfectant approved
by, 42
USPSTF. See United States Preventive
Services Task Force
V
Vaccine-Preventable Diseases (VPDs),
PHL testing for, 591–592
Vaccinia virus (VACV), 457
historic standards for diagnosis of, 458
replication cycle of, 460
taxonomy and characterization of, 5
Vaginal cancer, 415
Validation
quality assurance with, 33–34
systems for nucleic acid extraction, 126
Varicella (Chickenpox), 5
Varicella-zoster virus (VZV)
antiviral susceptibility testing for
clinical indications for, 203
definitions, antiviral resistance, 203–204
variables of, 203–204
antiviral therapies and treatment for,
203–204, 366
assays for, 204, 220, 221
best practices for, 369–370
biological characteristics of, 363–364
clinical significance of, 365
detection and diagnosis of
algorithm for, 368
analytical, 369
antibody, 369
cell culture in, 81, 87
nucleic acid amplification tests, 369
postanalytical, 369
preanalytical, 369
epidemiology of, 364
mechanism of action of therapies for,
367
mutations in POL gene of, 221
mutations in TK gene of, 220
prevention of, 367
specimen collection for, 69
specimen information for congenital
infections with, 68
specimen information for exanthems
with, 61
specimen information for neurological
infections with, 63
specimen information for ocular
infections with, 70
viral classification of, 363–364
Varicellosis, 5
Variola virus (VARV), 457, 459
historic standards for diagnosis of,
458
VEEV. See Venezuelan equine encephalitis
virus
Venezuelan encephalitis, specimen
information for neurological
infections with, 62
Venezuelan equine encephalitis virus
(VEEV), 494
clinical significance of, 500
taxonomy and characterization of, 10
Verigene, 124
Vero/SLAM cell line, 300
Verruca vulgaris (Common wart), 415
Vesiculovirus
Vesicular stomatitis
Viral antigen detection, 95–103
application of, 100–102
basic concepts of, 95–100
diagnostic hybrids proficiency panel in, 96
enzyme immunoassay, 98–100, 101
immunochromatography, 96–98, 101
immunofluorescence, 95–96, 101
immunohistochemical staining, 98–100
membrane EIA, 98, 99, 101
microwell-based EIA, 99–100, 101
quality assurance for, 102–103
reporting for, 102–103
tube EIA, 99–100
Viral diseases
diagnosis of, 572–575
genetic factors in susceptibility to, 568–572
complement deficiency, 571
C-type lectins, 568, 569–571
hypogammaglobulinemia, 571
immune cell deficiencies, 571
inflammosome defects, 571
RLRs, 568, 569
TLRs, 568, 569
host response patterns in diagnostics for, 573
human susceptibility and response to, 567–575
genetic factors in, 568–572
receptor binding with, 569
immune response to, 568
monitoring of, 572–575
predicting outcomes for, 572–575
monitoring host factors in, 573
single-molecule markers for, 572
Viral intestinal infection, 8
taxonomy and characterization of, 7
Viral isolation, 79–90
cell cultures types in, 79, 80
common viruses in, 86–88
diagnostic applications of, 89–90
equipment needed for, 79–80
identification of, 83
quality assurance for, 88–89
sensitivity in, 79
supplies needed for, 79–80
troubleshooting for, 88–89
Viral loads. See Quantitative molecular methods
Viral meningitis, enteroviruses with, 282–283
Viral microarray-based assays, 245
Viral serology, quality assurance for, 31–32
Viral transport medium (VTM), 72
Viral warts, taxonomy and characterization of, 6
Virome, 174. See also Human virome
Viromics, 189
Viruses
biological pressures driving evolution of, 4
classification methods for, 14–15
defined, 3
escape theory of, 3
factors separating from other forms of life, 4
historical description of, 3
quality assurance in study of, 27
taxa infecting humans, 4
taxonomy of, 3–22
viral proteins functions with, 414
Virus genotyping, 191–192
Volepox virus, 459
VPDs. See Vaccine-Preventable Diseases
VTM. See Viral transport medium
Valvar cancer, 415
VZV. See Varicella-zoster virus
W
WEEV. See Western equine encephalitis virus
Wesselsbron, 9
Western blot
application of, 113–114
HTLV testing with, 538–539
limitations of, 113
method for, 113
quality assurance for, 113
Western equine encephalitis virus (WEEV), 494
epidemiology of, 498
specimen information for neurological infections with, 62
taxonomy and characterization of, 10
West Nile virus (WNV), 496
clinical significance of, 501
database website for, 18
epidemiology of, 498–499
specimen collection for, 66
specimen information for neurological infections with, 62
taxonomy and characterization of, 9
X
X-linked lymphoproliferative syndrome (XLP), 571
EBV associated with, 389, 392, 395
Y
Yaba Monkey, 459
Yaba monkey tumor virus, 6
Yatapoxviruses
clinical signs, symptoms, and severity for, 464
diagnoses of, 464
differential diagnoses for, 464–465
epidemiology of, 464
geographical distribution of, 464
historic standards for diagnosis of, 458
incidence of, 464
lesion histopathology for, 464
pathogenesis of, 464
prevalence of, 464
taxonomy and characterization of, 6
transmission of, 464
Yellow fever, 9, 19
jungle, 19
sylvatic, 19
urban, 19
Yellow fever virus (YFV), 496
clinical significance of, 501
epidemiology of, 499
Z
Zaire ebolavirus, 12
Zero-mode waveguide (ZMW), 176
Zika virus, 496
epidemiology of, 499
taxonomy and characterization of, 9
ZMWP. See Zero-mode waveguide
Zoster (Herpes zoster), taxonomy and characterization of, 5